R. Bociek

W. Chan, D. Weisenburger, J. Armitage, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation

J. Armitage, P. Bierman, R. Bociek, 2007 .

Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma

J. Armitage, P. Bierman, R. Bociek, 2021, Annals of Hematology.

Splenic marginal zone lymphoma: villous, not necessarily villainous.

R. Bociek, 2012, Oncology.

Leukemic diffuse large B-cell lymphoma in a patient with myeloproliferative disorder.

T. Greiner, J. Armitage, K. Fu, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.

J. Armitage, P. Bierman, R. Bociek, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Polycomb response element-binding sites in the MDR of CLL: Potential tumor suppressor regulation

Christine E. Cutucache, D. Weisenburger, P. Bierman, 2013 .

PRE-binding sites in the MDR of CLL: Potential Tumor Suppressor Regulation

Christine E. Cutucache, D. Weisenburger, P. Bierman, 2013 .

Molecular Determinants of Lymph Node Microenvironment Induced Host Immune Tolerance In CLL: Role for CAV1, PTPN6, and PKCβ In the Process

D. Weisenburger, P. Bierman, R. Bociek, 2010 .

Clinical Heterogeneity of CLL: Role for Immune Dysregulation Mediated by the Lymph Node Microenvironment.

P. Bierman, R. Bociek, S. Joshi, 2009 .

Molecular Basis of Proliferation/Survival and Migration of CLL in Peripheral Blood, Bone Marrow and Lymph Nodes

D. Weisenburger, R. Bociek, S. Joshi, 2008 .

Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia

J. Armitage, P. Bierman, R. Bociek, 2016, American journal of hematology.

Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)

R. Bociek, R. Martell, J. Kuruvilla, 2008 .

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

R. Bociek, G. Salles, G. Martinelli, 2014 .

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

R. Advani, R. Bociek, J. Vose, 2014 .

Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database

R. Bociek, V. Shostrom, A. Kallam, 2021, Annals of Hematology.

Lymphoma 2006: classification and treatment.

J. Armitage, P. Bierman, R. Bociek, 2006, Oncology.

Adult Burkitt's lymphoma.

R. Bociek, 2005, Clinical lymphoma.

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

R. Bociek, A. Chanan-Khan, K. Rai, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia

J. Armitage, P. Bierman, R. Bociek, 2007, Clinical Cancer Research.

Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.

J. Armitage, P. Bierman, R. Bociek, 2007, Cancer genetics and cytogenetics.

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.

R. Bociek, S. Joshi, H. Band, 2016, Blood.

Hodgkin's disease and non-Hodgkin's lymphoma.

R. Bociek, J. Armitage, 1999, Current opinion in hematology.

Cell of origin fails to predict survival in patients with diffuse large B‐cell lymphoma treated with autologous hematopoietic stem cell transplantation

W. Chan, T. Greiner, D. Weisenburger, 2012, Hematological Oncology.

Adult Burkitt lymphoma: advances in diagnosis and treatment.

W. Chan, D. Weisenburger, J. Armitage, 2008, Oncology.

A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.

W. Chan, T. Greiner, D. Weisenburger, 2003, Blood.

Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.

J. Armitage, P. Bierman, R. Bociek, 2015, Clinical lymphoma, myeloma & leukemia.

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

R. Bociek, F. Hernandez-Ilizaliturri, A. Younes, 2016, Haematologica.

Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.

J. Armitage, R. Bociek, J. Vose, 2016, Future oncology.

Is post-operative radiation for renal cell carcinoma justified?

R. Bociek, D. Salhani, I. Aref, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Radiotherapy for localized prostate carcinoma

R. Bociek, G. Perry, J. Crook, 1997, Cancer.

BK Viremia as a Predictor of Hemorrhagic Cystitis in Adults During the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplantation.

R. Bociek, J. Meza, V. Shostrom, 2018, Transplantation proceedings.

Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT)

J. Armitage, P. Bierman, R. Bociek, 2013, Bone Marrow Transplantation.

Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.

R. Bociek, Steven M. Johnson, J. Sanmann, 2018, Human pathology.

Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience

T. Greiner, J. Armitage, Lynette M. Smith, 2016, Leukemia & lymphoma.

Hematopoietic stem-cell transplantation in mantle-cell lymphoma

J. Armitage, P. Bierman, R. Bociek, 2005, Nature Clinical Practice Oncology.

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

R. Bociek, F. Cavalli, S. Lade, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

W. Chan, T. Greiner, D. Weisenburger, 2005, Modern Pathology.

Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline‐Based Therapy

W. Chan, T. Greiner, D. Weisenburger, 2017, Clinical lymphoma, myeloma & leukemia.

Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.

J. Armitage, P. Bierman, R. Bociek, 2013, Clinical lymphoma, myeloma & leukemia.

The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation.

J. Armitage, P. Bierman, R. Bociek, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.

J. Armitage, R. Bociek, W. Sanger, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Role of radiation therapy in primary mediastinal large B‐cell lymphoma in rituximab era: A US population‐based analysis

J. Armitage, R. Bociek, J. Vose, 2015, American journal of hematology.

5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results

R. Bociek, M. Dyer, T. Kipps, 2011 .

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

R. Bociek, G. Salles, G. Martinelli, 2017, Haematologica.

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.

R. Bociek, J. Paulus, Y. Oki, 2011, The Lancet. Oncology.

Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.

D. Weisenburger, J. Armitage, Lynette M. Smith, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Bariatric Implant-Associated Anaplastic Large-Cell Lymphoma.

T. Greiner, P. Bierman, R. Bociek, 2017, Journal of oncology practice.

High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis.

R. Bociek, S. Gandini, L. Santoro, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

W. Chan, J. Armitage, P. Bierman, 2010 .

High-Dose Therapy (HDT) with Hematopoietic Stem Cell Transplantation (HSCT) is effective therapy for patients with Non-Hodgkin Lymphoma (NHL) and Central Nervous System (CNS) involvement

J. Armitage, P. Bierman, R. Bociek, 2010 .

Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study.

D. Weisenburger, J. Armitage, P. Bierman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?

R. Bociek, J. Vose, V. Bhatt, 2021, Future oncology.

Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.

J. Armitage, P. Bierman, R. Bociek, 2015, Clinical lymphoma, myeloma & leukemia.

Near Misdiagnosis of Glioblastoma as Primary Central Nervous System Lymphoma

R. Bociek, V. Bhatt, N. Shonka, 2014, Journal of clinical medicine research.

Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

T. Greiner, J. Armitage, K. Fu, 2020, Blood.

MYC and BCL2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab

W. Chan, T. Greiner, D. Weisenburger, 2014, British journal of haematology.

Autologous and allogeneic hematopoietic stem cell transplantation for diffuse large B-cell lymphoma

R. Bociek, V. Bhatt, S. Giri, 2016 .

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

W. Chan, T. Greiner, D. Weisenburger, 2015, Leukemia & lymphoma.

Cardiac Magnetic Resonance Imaging for the Assessment of the Myocardium After Doxorubicin-based Chemotherapy

J. Armitage, P. Bierman, R. Bociek, 2015, American journal of clinical oncology.

Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma.

B. Nathwani, W. Chan, T. Greiner, 2018, Human pathology.

High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma.

J. Armitage, P. Bierman, R. Bociek, 2011, Clinical lymphoma, myeloma & leukemia.

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

R. Bociek, P. Mclaughlin, A. Younes, 2007 .

Phase II Study of Mocetinostat ( MGCD 0103 ) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma

R. Bociek, J. Paulus, Y. Oki, 2016 .

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

R. Advani, R. Bociek, Sonali M. Smith, 2017 .

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

R. Bociek, R. Gascoyne, L. Gordon, 2012 .

Bone marrow transplantation--current concepts.

R. Bociek, J. Armitage, D. Stewart, 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

Patients with Follicular Lymphoma, Grade 3, Have a Prolonged Relapse-Free Survival Following Aggressive Combination Chemotherapy.

D. Weisenburger, J. Armitage, Lynette M. Smith, 2004 .

The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study

R. Bociek, A. Younes, Y. Kasamon, 2011 .

Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.

R. Bociek, J. Leonard, B. Cheson, 2004 .

Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study

J. Armitage, P. Bierman, R. Bociek, 2023, British journal of haematology.

Progress in TP53-Deficient Chronic Lymphocytic Leukemia: More Questions Than Answers.

R. Bociek, 2017, Journal of oncology practice.

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

J. Armitage, P. Bierman, R. Bociek, 2016 .

Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?

D. Weisenburger, J. Armitage, P. Bierman, 2013, Clinical lymphoma, myeloma & leukemia.

Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.

J. Armitage, R. Bociek, J. Vose, 2016, Clinical lymphoma, myeloma & leukemia.

Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.

J. Armitage, P. Bierman, R. Bociek, 2007, Leukemia & lymphoma.

Hematopoietic growth factors.

J. Armitage, R. Bociek, J. Armitage, 1996, CA: a cancer journal for clinicians.

Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.

J. Armitage, P. Bierman, R. Bociek, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

R. Advani, R. Bociek, J. Vose, 2018, Blood.

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.

R. Bociek, H. Band, V. Shukla, 2016, Blood.

Clinicopathologic Features, Management and Outcomes of Blastoid Variant (BV) of Mantle Cell Lymphoma (MCL): A Nebraska Lymphoma Study Group (NLSG) Experience

T. Greiner, J. Armitage, P. Bierman, 2014 .

Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma

J. Armitage, P. Bierman, R. Bociek, 2012 .

Adult Burkitt lymphoma: advances in diagnosis and treatment.

W. Chan, D. Weisenburger, J. Armitage, 2008, Oncology.